Tolterodine ER Versus Immediate Release: Leaks and Dry Mouth

If tolterodine helps your urgency but leaves your mouth uncomfortable, check the formulation on the pharmacy label before your next review. Ask whether you take an extended-release capsule or an immediate-release tablet, and bring the prescribed strength and schedule.

What the comparison measured

A 2001 double-blind, randomized trial¹ enrolled 1,529 adults, 81% women, for 12 weeks. Participants had at least eight urinations per 24 hours and at least five urge-incontinence episodes per week.¹

The table shows the median percentage reduction in weekly urge-leak episodes from baseline and the percentage reporting dry mouth.¹

Regimen	Results
Extended-release tolterodine, 4 mg once daily	71% fewer leaks; 23% dry mouth
Immediate-release tolterodine, 2 mg twice daily	60% fewer leaks; 30% dry mouth
Placebo	33% fewer leaks; 8% dry mouth

Both active treatments significantly reduced urge-leak episodes compared with placebo. The 71% figure describes a median reduction from baseline, rather than the proportion of participants who became completely dry.¹

Dry mouth was seven percentage points less frequent with extended release than immediate release, about a 23% relative reduction using rounded rates.¹

These are 12-week findings in people with urge leaks. They cannot establish long-term cognitive safety or predict an individual response.

Check the capsule instructions before discussing a switch

The current U.S. prescribing information identifies extended-release tolterodine as an antimuscarinic for overactive bladder with urgency, frequency and urge incontinence. It specifies 4 mg once daily, swallowed whole with water. The dose may be lowered to 2 mg for response or tolerability, though efficacy data at 2 mg are limited.²

A 2-mg daily dose is specified for certain kidney or liver impairment and with potent CYP3A4 inhibitors, including clarithromycin, ketoconazole and ritonavir. Severe liver impairment and very severe kidney impairment have further restrictions.²

The trial’s two regimens are evidence to discuss with a prescriber. They are not instructions to combine tablets, open capsules or change the timing yourself. Ask the pharmacist to confirm the new directions if your prescription changes.

The label contraindicates use with urinary retention, gastric retention or uncontrolled narrow-angle glaucoma. It warns that other anticholinergic medicines can increase dry mouth, constipation, blurred vision and sleepiness. A history of QT prolongation and certain heart-rhythm medicines also requires consideration.²

Bring the names of nonprescription sleep, allergy and cold products as well as prescriptions. A medication review needs the actual ingredients in each product.

Less dry mouth does not settle every treatment question

The 2024 AUA/SUFU guideline favors extended-release over immediate-release antimuscarinic formulations for reducing side effects. It also calls for discussing the potential risk of dementia and cognitive impairment when prescribing this medication class.³

Choosing a formulation with less dry mouth does not answer that separate, longer-term question. Ask about the expected treatment duration, your other medicines and whether an alternative class suits your situation.

The guideline notes that beta-3 agonists appear to cause less dry mouth and constipation than antimuscarinics. Different options have their own cautions, so the decision should include your medical history and the outcome you want from treatment.³

Give bothersome symptoms a place in the review

NHS⁴ advice includes sugar-free gum or sweets for dry mouth and notes that persistent dryness can contribute to tooth decay or fungal infection. Speak with your pharmacist or clinician if a side effect remains troublesome. Seek urgent medical help if you cannot pee at all. New difficulty starting or fully emptying the bladder also needs prompt advice. Sudden mouth, tongue or throat swelling or trouble breathing requires emergency care.⁴

The AUA/SUFU panel recommends assessing benefit and side effects within 4 to 8 weeks of starting overactive-bladder medication.³ Arrange that review when the prescription begins, with earlier contact for concerning symptoms.

Bring a before-and-after bladder record: trips to the toilet, urge leaks, pad use and whether dry mouth interferes with eating, talking or sleep. Ask: “Has the improvement been enough to continue this regimen, and what should change if the side effects remain bothersome?”

Laugh, Sneeze, Jump, Chapter 9’s “What to Say in the Room,” recommends bringing an earlier and a current three-day bladder record, every medicine you take and the activity you want back. Those particulars give a medication review something concrete to work toward.